NCT02203825View on ClinicalTrials.gov

Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeMultiple Myeloma
Interventions
BIOLOGICAL

CM-CS1 T-cell infusion

Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Celyad Oncology SA
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Celyad Oncology SA

INDUSTRY

NCT02203825 - Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | Biotech Hunter | Biotech Hunter